CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
Sotatercept +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01712308
NCT01712308Phase 2Completed
CompareCT.gov

A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia

M.D. Anderson Cancer Center·interventional·Posted Oct 23, 2012·Updated Oct 10, 2023

In Brief

A Phase 2 clinical trial evaluating Sotatercept and Ruxolitinib for Anemia and 2 related conditions. Completed, enrolled 56 participants across 1 site.

Detailed Summary

This phase II trial studies the side effects of and how well sotatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis or anemia. Sotatercept may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 23, 2012
Enrollment StartFeb 21, 2013
Primary CompletionMay 24, 2022
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 13.7 years ago

Interventions

Sotaterceptbiological

Given SC

Ruxolitinibdrug